CN102802419A - 刺猬(hedgehog)抑制剂 - Google Patents

刺猬(hedgehog)抑制剂 Download PDF

Info

Publication number
CN102802419A
CN102802419A CN2011800055507A CN201180005550A CN102802419A CN 102802419 A CN102802419 A CN 102802419A CN 2011800055507 A CN2011800055507 A CN 2011800055507A CN 201180005550 A CN201180005550 A CN 201180005550A CN 102802419 A CN102802419 A CN 102802419A
Authority
CN
China
Prior art keywords
alkyl
aryl
halogen
heteroaryl
conh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800055507A
Other languages
English (en)
Chinese (zh)
Inventor
让-米歇尔·韦尼耶
约翰·梅
帕特里克·奥康纳
威廉·皮普卡
安东尼·平克顿
皮埃尔-伊夫·布诺
斯特凡妮·霍普金斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Selexagen Therapeutics Inc
Original Assignee
Selexagen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selexagen Therapeutics Inc filed Critical Selexagen Therapeutics Inc
Publication of CN102802419A publication Critical patent/CN102802419A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN2011800055507A 2010-01-07 2011-01-06 刺猬(hedgehog)抑制剂 Pending CN102802419A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29312810P 2010-01-07 2010-01-07
US61/293,128 2010-01-07
PCT/US2011/020416 WO2011085128A1 (en) 2010-01-07 2011-01-06 Hedgehog inhibitors

Publications (1)

Publication Number Publication Date
CN102802419A true CN102802419A (zh) 2012-11-28

Family

ID=44305789

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800055507A Pending CN102802419A (zh) 2010-01-07 2011-01-06 刺猬(hedgehog)抑制剂

Country Status (10)

Country Link
US (1) US9174949B2 (OSRAM)
EP (1) EP2521451A4 (OSRAM)
JP (1) JP2013516480A (OSRAM)
KR (1) KR20120099155A (OSRAM)
CN (1) CN102802419A (OSRAM)
AU (1) AU2011204370B2 (OSRAM)
CA (1) CA2785204C (OSRAM)
MX (1) MX2012007929A (OSRAM)
PH (1) PH12012501389A1 (OSRAM)
WO (1) WO2011085128A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025232650A1 (zh) * 2024-05-07 2025-11-13 南京同诺康医药科技有限公司 Kif18a抑制剂及其制备方法和用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
JP2013516480A (ja) 2010-01-07 2013-05-13 セレクサゲン セラピューティクス，インク． ヘッジホッグ阻害剤
WO2014043715A1 (en) * 2012-09-17 2014-03-20 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN107074839A (zh) * 2013-08-29 2017-08-18 贝勒医学院 用于治疗代谢和体重相关的病症的组合物和方法
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
US10521327B2 (en) * 2016-09-29 2019-12-31 2236008 Ontario Inc. Non-coupled software lockstep
JP7260540B2 (ja) * 2017-07-11 2023-04-18 サイティアー セラピューティクス，インコーポレイティド Ｒａｄ５１阻害剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070105899A1 (en) * 2004-04-16 2007-05-10 Nobuyasu Suzuki Benzene compounds
WO2009030952A2 (en) * 2007-09-05 2009-03-12 Astrazeneca Ab Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2009146013A1 (en) * 2008-03-31 2009-12-03 Georgetown University Myosin light chain phosphatase inhibitors
WO2009151495A2 (en) * 2008-03-18 2009-12-17 Amgen Inc. Oxazole compounds, compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362369B2 (en) * 1997-11-25 2002-03-26 Nihon Nohyaku Co., Ltd. Phthalic acid diamide derivatives fluorine-containing aniline compounds as starting material, agricultural and horticultural insecticides, and a method for application of the insecticides
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
CN1930144A (zh) 2004-03-09 2007-03-14 贝林格尔·英格海姆药物公司 可用作细胞因子产生抑制剂用于治疗慢性炎性疾病的3,4’－杂环基－1,2,3－三唑－1－基－n－芳基苯甲酰胺
KR20160058972A (ko) 2004-09-02 2016-05-25 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
CN101083996A (zh) 2004-10-28 2007-12-05 Irm责任有限公司 作为hedgehog途径调节剂的化合物和组合物
JP5225857B2 (ja) 2005-11-14 2013-07-03 ジェネンテック，インコーポレイティド ヘッジホッグシグナル伝達のビスアミド阻害剤
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
TW200918521A (en) 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
WO2010127152A2 (en) * 2009-04-29 2010-11-04 Irm Llc Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
WO2011014888A1 (en) 2009-07-31 2011-02-03 Selexagen Therapeutics Novel hedgehog inhibitors
JP2013516480A (ja) 2010-01-07 2013-05-13 セレクサゲン セラピューティクス，インク． ヘッジホッグ阻害剤
WO2011085261A1 (en) 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070105899A1 (en) * 2004-04-16 2007-05-10 Nobuyasu Suzuki Benzene compounds
WO2009030952A2 (en) * 2007-09-05 2009-03-12 Astrazeneca Ab Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2009151495A2 (en) * 2008-03-18 2009-12-17 Amgen Inc. Oxazole compounds, compositions and methods of use
WO2009146013A1 (en) * 2008-03-31 2009-12-03 Georgetown University Myosin light chain phosphatase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PASCA ET AL: "Hedgehog signalling in cancer formation and maintenance》", 《NATURE REVIEWS/CANCER》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025232650A1 (zh) * 2024-05-07 2025-11-13 南京同诺康医药科技有限公司 Kif18a抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
EP2521451A1 (en) 2012-11-14
JP2013516480A (ja) 2013-05-13
CA2785204C (en) 2016-01-05
CA2785204A1 (en) 2011-07-14
AU2011204370B2 (en) 2015-03-05
MX2012007929A (es) 2012-11-21
KR20120099155A (ko) 2012-09-06
EP2521451A4 (en) 2013-08-21
AU2011204370A1 (en) 2012-07-05
PH12012501389A1 (en) 2012-10-29
US20130012513A1 (en) 2013-01-10
WO2011085128A1 (en) 2011-07-14
US9174949B2 (en) 2015-11-03

Similar Documents

Publication Publication Date Title
CN102802419A (zh) 刺猬(hedgehog)抑制剂
KR102475498B1 (ko) 리신 특이적 데메틸라아제-1의 억제제
CN105026372B (zh) 组蛋白脱甲基酶抑制剂
JP6276378B2 (ja) ヒストンデメチラーゼ阻害剤
JP6256771B2 (ja) ヒストンデメチラーゼ阻害剤
JP4828421B2 (ja) 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
WO2012008564A1 (ja) 含窒素芳香族複素環誘導体
TW201623254A (zh) 離胺酸特異性去甲基酶－１之抑制劑
WO2011085261A1 (en) Hedgehog inhibitors
CN107073006A (zh) 组蛋白脱甲基酶抑制剂
JP2023085300A (ja) ヒストンデメチラーゼ阻害剤
JP2006522735A (ja) ミックス系統キナーゼモジュレータ
JP2023542845A (ja) Ｒｎａヘリカーゼｄｈｘ３３を阻害する多環式化合物及びその応用
WO2011014888A1 (en) Novel hedgehog inhibitors
JP2019508447A (ja) ヒストンデメチラーゼ阻害剤
KR100248643B1 (ko) 아릴 및 헤테로아릴 알콕시나프탈렌 유도체
JP7445266B2 (ja) タンキラーゼ阻害剤としての１，２，４－トリアゾール誘導体
HK1179113A (en) Hedgehog inhibitors
WO2024259060A1 (en) Inhibitors of met kinase
CN114478409A (zh) 组蛋白脱甲基酶抑制剂
WO2025030117A1 (en) Ferroptosis inducers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1179113

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121128